Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029

Rhea-AI Filing Summary

Agomab Therapeutics, a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, reported half year 2026 results for the period ended June 30, 2026. The company recorded a net loss of €30,971 thousand on total operating expenses of €35,138 thousand, including research and development expenses of €22,967 thousand and general and administrative expenses of €12,171 thousand.

Agomab strengthened its balance sheet through a Nasdaq initial public offering, raising $208 million in gross proceeds. Cash and cash investments totaled €252 million at June 30, 2026, including €221,588 thousand of cash and cash equivalents, which management expects to support the cash runway into the first half of 2029.

Clinically, Agomab reported regulatory alignment with the U.S. FDA on key elements of the NOV-ERA Phase 2b study of ontunisertib in Fibrostenosing Crohn’s Disease, and plans to initiate this trial and a Phase 2 study of AGMB-447 in idiopathic pulmonary fibrosis in the second half of 2026. Topline data from the OLE part of the STENOVA study with ontunisertib and from the Phase 1b IPF cohort with AGMB-447 are expected in the coming months.

Positive

• $208 million in gross IPO proceeds and total cash and cash investments of €252 million at June 30, 2026 provide a multi-year cash runway that management expects to extend into the first half of 2029, supporting planned Phase 2 clinical development.

Negative

• Agomab reported a sizeable net loss of €30,971 thousand for the six months ended June 30, 2026, driven by €35,138 thousand in operating expenses, highlighting the cash burn typical of a clinical-stage biopharmaceutical company without approved products.

Filing Explained

By June 30, 2026, 163,899 thousand euros of net capital-increase proceeds were recorded, but dilution and use of funds remain unquantified.

AgomAb filed a Form 6-K, an interim report used by a foreign private issuer to furnish material information, covering the six months ended June 30, 2026 and a business update. By that date, its cash-flow statement recorded €163,899 thousand of net proceeds from a capital increase, while the balance sheet reported €265,376 thousand of equity and €221,588 thousand of cash and cash equivalents.

Issuing additional shares reduces an existing holder’s percentage ownership absent offsetting changes, but this filing does not state the IPO share count or resulting dilution. It also does not identify a specific use of the capital-increase proceeds, so the filing sizes the cash raised without allocating it to particular programs or expenses.

The filing states that its information, other than specified executive quotes, is incorporated by reference into the company’s Form S-8 registration statement. That incorporation is a registration-document action; this 6-K does not report shares being offered or sold under that registration statement.

Key Figures

Net loss: €30,971 thousand Total operating expenses: €35,138 thousand Research and development expenses: €22,967 thousand +5 more

8 metrics

Net loss €30,971 thousand Loss for the six months ended June 30, 2026

Total operating expenses €35,138 thousand Operating expenses for the six months ended June 30, 2026

Research and development expenses €22,967 thousand R&D expenses for the six months ended June 30, 2026

Cash and cash investments €252 Million Cash and cash investments at June 30, 2026

Cash and cash equivalents €221,588 thousand Cash and cash equivalents at June 30, 2026

IPO gross proceeds $208 Million Gross proceeds from initial public offering

Net cash from financing activities €165,087 thousand Net cash flow from financing activities for the six months ended June 30, 2026

Basic and diluted loss per share €(0.80) Basic and diluted loss per share for the six months ended June 30, 2026

Key Terms

Fibrostenosing Crohn’s Disease, Idiopathic Pulmonary Fibrosis, Fast Track Designation, contingent consideration, +2 more

6 terms

Fibrostenosing Crohn’s Disease medical

"Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD)"

A form of Crohn’s disease in which ongoing inflammation causes scarring and narrowing of sections of the intestine, similar to how mineral buildup can harden and choke a garden hose. It matters to investors because this complication changes treatment needs, often reducing effectiveness of standard anti-inflammatory drugs and increasing demand for surgeries, medical devices, or specialty therapies—factors that shape market size, clinical trial design, regulatory risk and potential revenue.

Idiopathic Pulmonary Fibrosis medical

"Phase 2 study in with AGMB-447 in IPF (Idiopathic Pulmonary Fibrosis)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

Fast Track Designation regulatory

"Ontunisertib has received U.S. FDA Fast Track Designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

contingent consideration financial

"Non-current contingent consideration amounted to 3,437 and current contingent consideration 6,737"

Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

Right-of-use assets financial

"Right-of-use assets totaled 962 as of June 30, 2026"

Right-of-use assets are the rights a company gains to use a physical space or equipment under a lease agreement. They are recorded as assets on the company's balance sheet, reflecting the value of future benefits from the leased item. For investors, these assets provide a clearer picture of a company's obligations and resources related to leasing arrangements, helping to assess its financial health and operational commitments.

share-based payment expenses financial

"Share-based payment expenses were 2,467 for the six months ended June 30, 2026"

Share-based payment expenses are the recorded costs a company recognizes when it compensates employees, consultants or suppliers with its own stock or stock-based instruments (like options or restricted shares) instead of cash. Investors care because these costs reduce reported profits and can increase the number of shares outstanding over time, diluting ownership and affecting metrics such as earnings per share and valuation—similar to a business paying wages with gift cards that change who owns part of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/06/2026 - 04:07 PM Accepted by SEC EDGAR 08/06/2026 - 04:06 PM Learn about SEC filing dates

FAQ

What were Agomab Therapeutics (AGMB) key financial results for the first half of 2026?

Agomab reported a net loss of €30,971 thousand for the six months ended June 30, 2026, on total operating expenses of €35,138 thousand, including research and development expenses of €22,967 thousand and a basic and diluted loss per share of €0.80.

How much cash does Agomab Therapeutics (AGMB) have and what is its expected cash runway?

At June 30, 2026, Agomab held €252 million in cash and cash investments, including €221,588 thousand of cash and cash equivalents. Management expects this, together with IPO proceeds, to support the company’s cash runway into the first half of 2029.

How much did Agomab Therapeutics (AGMB) raise in its Nasdaq IPO?

Agomab’s Nasdaq initial public offering generated $208 million in gross proceeds. Related financing cash flows include €163,899 thousand from a capital increase, partially offset by €1,056 thousand of transaction costs and supported by €2,329 thousand of exchange gains on the IPO proceeds.

What upcoming clinical milestones did Agomab Therapeutics (AGMB) highlight for ontunisertib and AGMB-447?

Agomab plans to initiate its NOV-ERA Phase 2b study of ontunisertib in Fibrostenosing Crohn’s Disease and a Phase 2 study of AGMB-447 in idiopathic pulmonary fibrosis in the second half of 2026, with key topline data readouts expected in the coming months.

What regulatory progress has Agomab Therapeutics (AGMB) made with the FDA for ontunisertib?

Agomab reported regulatory alignment with the U.S. FDA on key elements of the NOV-ERA Phase 2b study design of ontunisertib in Fibrostenosing Crohn’s Disease. Ontunisertib has also received FDA Fast Track Designation, supporting its development in this high unmet-need indication.

What does the balance sheet of Agomab Therapeutics (AGMB) look like at June 30, 2026?

Total assets were €290,923 thousand, including €32,442 thousand in non-current assets and €258,481 thousand in current assets. Total equity stood at €265,376 thousand, with total liabilities of €25,547 thousand, reflecting a strong equity position after the IPO.

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

​

For the month of August 2026

​

Commission File Number: 001-43098

​

AgomAb Therapeutics NV

​

Posthoflei 1/6

2600 Antwerpen

Belgium

Tel: +32 3 318 91 70

(Address, Including Zip Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F x Form 40-F ¨

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

​

​

​

​

​

On August 6, 2026, AgomAb Therapeutics NV (the “Company”) issued a press release titled, “Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook,” announcing the Company’s results for the period ended June 30, 2026 and providing a business update. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference.

​

​

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Mr. Tim Knotnerus and Mr. Pierre Kemula included in Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-294220).

​

INDEX TO EXHIBITS

​

Number	​ ​ ​	Description
	​
99.1	​	Press Release of AgomAb Therapeutics NV dated August 6, 2026, announcing the Company’s results for the six months ended June 30, 2026.
	​
​	​	​
​	​	​
​	​	​
​	​	​
​	​	​
​	​	​
​	​	​

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

	AgomAb Therapeutics NV
Date: August 6, 2026	By:	/s/ Tim Knotnerus
		Tim Knotnerus
		Chief Executive Officer

​

Exhibit 99.1

​

​

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming Months --

-- On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in IPF in Second Half of 2026 --

-- Cash and Cash Investments at June 30, 2026 of €252 Million, including $208 Million in Gross Proceeds from Initial Public Offering (IPO), Expected to Support Cash Runway into First Half of 2029 --

​

Antwerp, Belgium, August 6, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the half year period ended June 30, 2026, and confirmed its outlook for the second half of 2026.

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,” said Tim Knotnerus, Chief Executive Officer of Agomab. “Our recent engagement with the FDA provides important support for our development strategy with ontunisertib, and we believe the NOV-ERA Phase 2b study will be a crucial next step in evaluating ontunisertib’s potential as a differentiated therapy to address the high unmet medical need in FSCD. As we head into a catalyst-rich second half of 2026, we especially look forward to the OLE results with ontunisertib and first IPF data with AGMB-447.”

Pierre Kemula, Chief Financial Officer of Agomab, added, “The first half of 2026 marked a defining moment for Agomab, with our Nasdaq IPO raising $208 million in gross proceeds, extending the cash runway into the first half of 2029. We are well-resourced to drive our clinical programs forward with both focus and discipline. As we look ahead to important milestones across our fibro-inflammatory disease portfolio, we are well positioned to deliver meaningful value for patients and shareholders alike.”

First Half 2026 Program Highlights and Anticipated Milestones

● Ontunisertib (AGMB-129), a gut-restricted small molecule inhibitor of ALK5 for the treatment of FSCD

o We announced the design of the NOV-ERA study, a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial designed to evaluate the efficacy and safety of ontunisertib in adults with symptomatic FSCD. We have aligned with the FDA on the NOV-ERA design, including the study’s primary efficacy endpoint of endoscopic passability at Week 24 as assessed by the SES-CD narrowing score, as well as several secondary efficacy endpoints relevant to patients with FSCD.

o The protocol has been submitted to the FDA and has cleared central Institutional Review Board (IRB) approval in the U.S. In addition, the study has received approval by Health Canada and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The Company has also submitted Clinical Trial Applications (CTAs) in multiple countries globally, including in the European Union and Asia Pacific

​

territories. We plan to initiate the NOV-ERA study following receipt of applicable regulatory and ethics approvals and expect to dose the first participants in the second half of 2026.

o We are progressing the OLE part of the STENOVA study (Part B) with ontunisertib in FSCD patients, with topline results expected in the coming months. The 48-week data may provide important insights into extended treatment with ontunisertib in FSCD patients.

o As of February 2026, the Data Safety and Monitoring Board has not raised any safety issue and has recommended for the OLE study to continue as per the protocol with 200mg BID ontunisertib for up to 60 weeks.

o The results of the 12-week placebo-controlled double-blind part of the STENOVA Phase 2a study with ontunisertib in FSCD (Part A) were presented as a late-breaker at the 21^st Congress of ECCO (ECCO’26) in Stockholm, Sweden in February 2026. The late-breaking presentation was also featured by Nature Reviews Gastroenterology & Hepatology as one of the highlights of ECCO’26.

​

● AGMB-447, an inhaled small molecule inhibitor of ALK5 in development for the treatment of IPF

​

o In January 2026, we announced positive interim results of the Phase 1 study of AGMB-447 in 108 healthy participants. The data pointed to a generally favorable safety, tolerability and pharmacokinetic profile of AGMB-447, with robust target engagement of ALK5 observed in the lungs of healthy participants.

o We have enrolled 10 participants in the IPF cohort of the Phase 1b study with AGMB-447. In this cohort, participants receive multiple doses of AGMB-447 or placebo over 14 days. We expect to report topline results from the IPF patient cohort in the coming months.

o We are on track to initiate a Phase 2 trial with AGMB-447 in IPF in the second half of the year.

o We were granted a patent covering the composition of matter of AGMB-447 by the United States Patent and Trademark Office (USPTO), solidifying the foundational intellectual property for AGMB-447 in the U.S.

​

Half Year 2026 Financial Results (consolidated)

● Cash Position: Cash, cash equivalents and short-term cash investments totaled €252.0 million as of June 30, 2026. In February 2026, we completed our IPO, in which we raised gross proceeds of approximately $208 million, including the proceeds from the underwriters’ partial exercise of their overallotment option, before deducting underwriting discounts and commissions and other offering expenses. We expect that our existing cash and cash investments, including the net proceeds from our IPO, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029.

● R&D Expenses: Research and development (R&D) expenses were €23.0 million for the six months ended June 30, 2026, as compared with €22.0 million for the six months ended June 30, 2025.

● G&A Expenses: General and administrative (G&A) expenses were €12.2 million for the six months ended June 30, 2026, as compared with €6.7 million for the six months ended June 30,2025. The increase of €5.5 million for the period mainly relates to one-off expenses incurred for the IPO.

● Net Loss: Net loss was €31.0 million for the six months ended June 30, 2026, compared to €26.9 million for the six months ended June 30, 2025.

Ontunisertib and AGMB-447 are investigational drugs and not approved by any regulatory authority. Their efficacy and safety have not been established.

​

​

Financial performance

Condensed consolidated statement of profit and loss (unaudited)

​	​	​	​	​
​	​	for the six months ended June 30,
(in thousands of €)	​ ​ ​	2026	​ ​ ​	2025
Research and development expenses		(22,967)		(22,022)
General and administrative expenses		(12,171)		(6,682)
Total operating expenses		(35,138)		(28,704)
​	​	​	​	​
Other operating income		1,079		1,312
Operating loss		(34,059)		(27,393)
​	​	​	​	​
Changes in fair value of financial liabilities		(438)		(256)
Financial expenses		(215)		(75)
Financial income		3,741		855
Loss before taxes		(30,971)		(26,868)
​	​	​	​	​
Income tax (expenses)/income		—		—
Loss for the period		(30,971)		(26,868)
​	​	​	​	​
Weighted average number of common shares outstanding		40,763,420		541,126
Basic and diluted loss per share (in €)		(0.80)		(63.86)

​

Condensed consolidated statement of comprehensive income or loss (unaudited)

​	​	​	​	​
​	​	for the six months ended June 30,
(in thousands of €)	​ ​ ​	2026	​ ​ ​	2025
Loss for the period		(30,971)		(26,868)
Items that may be reclassified to profit or loss		​		​
Foreign currency translation differences		66		(36)
Items that will not be reclassified to profit or loss		​		​
Remeasurements of post-employment benefit obligations		3		1
Other comprehensive income or loss for the period, net of tax		69		(35)
​	​	​	​	​
Total comprehensive income or loss for the period		(30,902)		(26,903)

​

​

​

Condensed consolidated statement of financial position (unaudited)

​	​	​	​	​
(in thousands of €)	​ ​ ​	As of June 30, 2026	​ ​ ​	As of December 31, 2025
Assets		​		​
Non-current assets		​		​
Intangible assets		20,110		20,110
Goodwill		8,612		8,612
Property, plant and equipment		443		503
Right-of-use assets		962		1,083
Other financial assets		13		11
Other non-current assets		2,302		2,150
Total non-current assets		32,442		32,469
​	​	​	​	​
Current assets		​		​
Other current assets		6,504		4,723
Current financial investments		30,389		30,096
Cash and cash equivalents		221,588		86,418
Total current assets		258,481		121,237
Total assets		290,923		153,706
​	​	​	​	​
Equity		​		​
Share capital		304,618		223,072
Share premium reserve		172,948		76,634
Retained earnings		(212,617)		(181,714)
Share-based payment reserves		14,784		13,877
Other reserves		(14,357)		(967)
Equity attributable to the owners of the parent		265,376		130,902
Total equity		265,376		130,902
​	​	​	​	​
Liabilities		​		​
Non-current liabilities		​		​
Non-current lease liabilities		910		1,005
Non-current contingent consideration		3,437		3,210
Non-current deferred income		1,129		—
Total non-current liabilities		5,476		4,215
​	​	​	​	​
Current liabilities		​		​
Current lease liabilities		229		249
Anti-dilutive warrants		—		—
Current contingent consideration		6,737		6,526
Trade and other payables		11,843		10,266
Deferred income and accrued charges		1,262		1,548
Total current liabilities		20,071		18,589
Total liabilities		25,547		22,804
Total equity and liabilities		290,923		153,706

​

Condensed consolidated statement of cash flows (unaudited)

​	​	​	​	​
​	​	for the six months ended June 30,
(In thousands €)	​ ​ ​	2026	​ ​ ​	2025
Net income/(loss) for the period		(30,971)		(26,868)
Adjustments for non-cash items:		​		​
Fair value (gain) loss on financial assets	​	(293)	​	​
Fair value gain (loss) on financial liabilities		438		256
Depreciation & amortization		173		195
Share-based payment expenses		2,467		2,597
Net foreign exchange losses (gains)		(2,219)		(53)
Interest expenses		33		37
Interest income		(1,048)		(764)
Operating cash flows before movements in working capital		(31,420)		(24,600)
Movements in working capital:		​		​
Decrease/(increase) in other current assets		(1,780)		(1,994)
Decrease/(increase) in other non-current assets		(152)		(138)
Increase/(decrease) in trade and other payables		1,576		(115)
Increase/(decrease) in current deferred income		(286)		1,156
Increase/(decrease) in non-current deferred income	​	1,129	​	—
​	​	​	​	​
Interest paid		(32)		(5)
Interest received		1,048		764
Net cash flow from /(used in) operating activities		(29,917)		(24,932)
​	​	​	​	​
Payment of contingent consideration from previous acquisition		—		(3,000)
Net cash flow from /(used in) investing activities		​		(3,000)
​	​	​	​	​
Repayment of lease liabilities		(149)		(148)
Proceeds from capital increase, net of issuance costs		163,899		—
Transaction costs paid		(1,056)		—
Exchange gains from currency conversion on proceeds from capital increase		2,329		—
Proceeds from exercise of stock options		64		—
Net cash flow from /(used in) financing activities		165,087		(148)
​	​	​	​	​
Net increase/(decrease) in cash and cash equivalents		135,170		(28,080)
​	​	​	​	​
Cash and cash equivalents at beginning of the period		86,418		171,459
Effect of foreign exchange rate changes		​		—
Cash and cash equivalents at end of the period		221,588		143,379

​

​

​

About ontunisertib

Ontunisertib (AGMB-129) is an oral small molecule GI-restricted inhibitor of ALK5 (or TGF-β RI) currently in clinical development for the treatment of Fibrostenosing Crohn’s Disease (FSCD). TGF-β is a major driver of fibrosis. Ontunisertib is specifically designed to inhibit ALK5/TGF-β in the GI-tract. Rapid first-pass metabolism in the liver prevents clinically relevant systemic exposure, potentially delivering an improved safety profile over systemically available inhibitors in this class. Ontunisertib has received U.S. FDA Fast Track Designation.

About Fibrostenosing Crohn’s Disease

Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding our expected cash runway, including that we anticipate our cash and cash investments and IPO proceeds will extend our runway into the first half of 2029, our focus on the discovery and development of our pipeline of novel product candidates for fibro-inflammatory disorders, the design of planned Phase 2 clinical trials with ontunisertib for FSCD and AGMB-447 for IPF, our expectation to initiate our Phase 2b Study of ontunisertib in FSCD and our Phase 2 study of AGMB-447 in IPF in the second half of 2026, our interactions with regulatory authorities as well as statements regarding future data readouts, including our expectation to release topline data from the OLE part of the STENOVA study and of the Phase 1b IPF Study Cohort with AGMB-447 in the coming months. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; disruptions caused by our reliance on third party suppliers and service providers; the risk that our expectations and management’s guidance regarding our cash position and other financial estimates may be incorrect; and risks related to geopolitical conflicts and macro-economic events. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

​

​

Contacts

Investors

Sofie Van Gijsel

VP of Investor Relations

E-Mail: sofie.vangijsel@agomab.com

Phone: +1 781 296 1143

Media

Gretchen Schweitzer

Trophic Communications

E-Mail: agomab@trophic.eu

Phone: +49 172 861 8540

​

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 223.2 KB